Theravance Biopharma, Inc. (TBPH)
(Delayed Data from NSDQ)
$17.31 USD
-0.18 (-1.03%)
Updated Feb 25, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value D Growth B Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.
JNJPositive Net Change GSKNegative Net Change TBPHNegative Net Change VTRSNegative Net Change
biotechs earnings
Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TBPHNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line
by Zacks Equity Research
Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.
JNJPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
earnings medical
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.37% and 3.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
TBPHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TBPHNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Verona (VRNA) Initiates Pivotal COPD Studies on Ensifentrine
by Zacks Equity Research
Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.
AZNNegative Net Change GSKNegative Net Change TBPHNegative Net Change VRNAPositive Net Change
biotechs
Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma
by Zacks Equity Research
With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.
AZNNegative Net Change GSKNegative Net Change TBPHNegative Net Change INVANegative Net Change
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe
by Zacks Equity Research
Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.
PFEPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
biotechs pharmaceuticals
Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TBPHNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2
by Zacks Equity Research
Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.
JNJPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
earnings medical
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.26% and -28.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
TBPHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TBPHNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TBPHNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
USANA (USNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.
UTHRNegative Net Change USNAPositive Net Change TBPHNegative Net Change IONSNegative Net Change
pharmaceuticals
Theravance Doses First Patient in Phase II Coronavirus Study
by Zacks Equity Research
Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.
AZNNegative Net Change RHHBYNegative Net Change TBPHNegative Net Change FGENNegative Net Change
medical
Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TBPHNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling
by Zacks Equity Research
Mylan (MYL) beats on Q1 earnings but misses on sales.
PFEPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
earnings pharmaceuticals
Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.
JNJPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
earnings medical
Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -7.55% and 10.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
TBPHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TBPHNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TBPHNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TBPHNegative Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply
by Zacks Equity Research
Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.
PFEPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
medical pharmaceuticals
Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.
PFEPositive Net Change MYLPositive Net Change GSKNegative Net Change TBPHNegative Net Change
medical pharmaceuticals
Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.
JNJPositive Net Change PFEPositive Net Change MYLPositive Net Change TBPHNegative Net Change
earnings medical